Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) is a medical technology company focused on advancing the surgical management of bunion and related midfoot deformities. As a commercial‑stage orthopaedic device company with a portfolio centered on 3D bunion correction, Treace regularly issues news on product innovation, clinical evidence, financial performance and capital structure.
On this page, readers can follow TMCI news covering quarterly and annual financial results, revenue trends, liquidity updates and guidance changes, as reported in the company’s earnings releases and related Form 8‑K filings. These updates often discuss factors such as surgeon adoption of Treace’s expanded bunion technology portfolio, procedure volume dynamics and the impact of broader economic conditions on elective bunion surgery.
Treace also announces new technologies and product milestones, including developments in its Lapiplasty 3D Bunion Correction System, minimally invasive systems such as Nanoplasty and Percuplasty, the SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants and IntelliGuide patient specific planning and cut guide technology. News items may highlight first surgical cases with new platforms, transitions from limited market release to full market release and surgeon feedback on workflow and clinical use.
In addition, TMCI news includes updates on clinical studies like ALIGN3D and MTA3D, where interim data on radiographic correction, recurrence, pain and patient‑reported outcomes are presented at orthopedic conferences. Investors can also see announcements about debt financing arrangements, investor conferences, investor days and changes in board composition or governance roles.
For investors, clinicians and analysts tracking TMCI stock, this news feed offers a consolidated view of Treace’s financial disclosures, product pipeline developments and market‑facing activities related to bunion and midfoot deformity surgery.
Treace Medical Concepts, Inc. (TMCI) has announced significant progress in its intellectual property portfolio, with 15 new patent applications filed and 7 utility patents granted in 2023. The granted patents cover innovative systems and methods for treating bunions, enhancing TMCI's position in the medical technology field. The company's total includes 58 granted patents globally and 84 pending applications, reflecting a commitment to advancing surgical management for bunions. CEO John T. Treace emphasized the importance of these innovations in improving patient care and the protection of proprietary technology.
Summary not available.
Treace Medical Concepts (TMCI) announced its fourth quarter and full year 2022 financial results, reporting a 49% increase in revenue for Q4 at $49.8 million, and a 50% increase for 2022 totaling $141.8 million. The gross margin stood at 80.4% for Q4 and 80.6% for the full year. The company also highlighted a strong adoption of the Lapiplasty® procedure, with nearly 1-in-4 U.S. bunion surgeons using it in 2022. Treace granted two new U.S. patents, expanding its portfolio to 40. A follow-on stock offering raised $107.5 million to support growth. The company expects 2023 revenue growth of 32% to 36% year-over-year.
Treace Medical Concepts (TMCI) announced a settlement with Fusion Orthopedics regarding a patent infringement lawsuit filed on March 29, 2022. The litigation, which took place in the U.S. District Court for Arizona, involved claims of patent, trademark, and copyright infringement related to the bunion surgery systems of both companies. While settlement terms remain confidential, Treace Medical is satisfied with the resolution. The company, which focuses on surgical treatments for bunion deformities, emphasizes that approximately 65 million Americans suffer from bunions, with an estimated 1.1 million being surgical candidates annually.
Treace Medical Concepts, Inc. (NASDAQ: TMCI) and Fusion Orthopedics, LLC have resolved their litigation concerning patent and trademark infringement. The lawsuit was initiated on March 29, 2022, when Treace Medical accused Fusion Orthopedics of infringing on its patents related to their respective bunion surgery products. Fusion Orthopedics countered with claims of non-infringement and invalidity. In March 2023, the parties reached a confidential settlement agreement, with Fusion Orthopedics expressing satisfaction with the outcome.
Treace Medical Concepts (NasdaqGS: TMCI) will announce its fourth quarter and full year 2022 financial results on March 7, 2023, following the market close. A conference call will take place at 4:30 pm ET to discuss these results. Treace focuses on surgical treatments for hallux valgus (bunions) through its proprietary Lapiplasty® 3D Bunion Correction™ Procedure. Approximately 65 million Americans are affected by bunions, with an estimated 1.1 million being surgical candidates annually. The company aims to improve surgical management standards for bunion deformities.
Treace Medical Concepts (NasdaqGS: TMCI) announced the latest interim clinical data from its ALIGN3D™ study during the 2023 ACFAS Annual Conference. The study analyzed 128 patients, revealing a remarkable 99.1% maintenance of bunion correction at 24 months and only a 0.9% recurrence rate. Patients experienced an average return to weight-bearing in just 8.1 days, with an 80.8% reduction in pain at 24 months. High satisfaction rates were reported, with 97.3% of patients satisfied at 36 months. Treace also showcased innovations like the Micro-Lapiplasty™ and SpeedPlate™ systems, set for commercialization later this year.
Treace Medical Concepts (NasdaqGS: TMCI) announced a public offering of 4,761,905 shares of its common stock at $21.00 per share, aiming to raise approximately $100 million in gross proceeds before commissions. The offering is set to close on February 10, 2023, pending customary conditions. All shares are offered by Treace with no involvement from selling stockholders. Additionally, underwriters have a 30-day option to purchase 714,285 additional shares. The funds will be utilized for general corporate purposes, including R&D and marketing. J.P. Morgan and Morgan Stanley are among the lead managers for the offering.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) has launched an underwritten public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. The funds raised will be allocated towards general corporate purposes, including research and development, sales and marketing, and capital expenditures. The offering, subject to market conditions, is backed by J.P. Morgan and Morgan Stanley as lead managers. Treace specializes in surgical treatments for bunions, with its patented Lapiplasty® 3D Bunion Correction™ procedure. The company aims to improve care standards for bunion surgery, addressing a significant patient population in the U.S.
Treace Medical Concepts (TMCI) announced preliminary unaudited results for Q4 and FY 2022, forecasting revenues between $49.1 million to $49.6 million for Q4 and $141.2 million to $141.7 million for the full year, marking a 50% growth year-over-year. This growth is attributed to strategic investments in direct sales and R&D. Treace is focused on advancing care standards for bunions and midfoot deformities through its Lapiplasty and Adductoplasty systems. The company plans to provide 2023 financial guidance in its upcoming earnings call.